At the 44th meeting on 14 January 2025, the Emergency Committee under the International Health Regulations (IHR) reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global targets to interrupt endemic WPV1 transmission in 2026 and to stop cVDPV2 outbreaks by 2028 with subsequent certification of WPV1 eradication and cVDPV2 elimination. Technical updates were received about the situation in the following countries: Afghanistan, Angola, Germany, Lao People’s Democratic Republic, Namibia, Pakistan and Papua New Guinea.
Wild poliovirus (WPV):
Circulating vaccine derived poliovirus (cVDPV):
The Committee unanimously concluded that the risk of international spread of poliovirus continues to constitute a Public Health Emergency of International Concern (PHEIC) and recommended extending the Temporary Recommendations for a further three months.
The Committee, after a thorough review of the epidemiological and programmatic situation, unanimously concluded that the event does not constitute a pandemic emergency.
Risk categories and advice aimed at reducing the risk of international spread of WPV1 and cVDPVs:
Chikungunya virus transmission is again increasing in Mayotte. Since 1 January 2026, more than 270 autochthonous confirmed cases have been reported, with an average of about 65 cases per week during the last two weeks of February.
Mayotte also experienced a chikungunya outbreak in 2025, with 1’270 confirmed cases and a peak of 232 cases in epidemiological week 21. The total number of cases was likely underestimated due to limited access to healthcare.
Elevated chikungunya transmission should be considered.
Optimal mosquito protection 24/7, also in cities, this also protects you against other mosquito-borne diseases. Vaccination against chikungunya is not licensed in Switzerland.
For vaccination recommendations, see ECTM statement.
In case of fever:
0